Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a...
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive...
Video illustrates the potential of LB1148 to reduce the formation of adhesions in gastrointestinal (GI) tissues and accelerate the time...
Topline proof-of-concept data in vitiligo patients expected in 1H 2023BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc....
REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...
As a certified partner, Linical will leverage Science 37’s Metasite™ to provide global access to patients beyond its existing brick-and-mortar site...
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable...
BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring...
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in...
Dr. Barratt will discuss disease burden and pathogenesis of IgAN, a common cause of kidney failure and a high unmet...
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into...
EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional...
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies...
PRESS RELEASE FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance...
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12)...
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - -...
BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma Amsterdam, The Netherlands, 17 November 2022 - BioGeneration Ventures...
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical...
Up to nine months durability of effect observed in patients aged 55 to 76 in the extension cohort following administration...